{"id":480221,"date":"2020-04-20T11:24:01","date_gmt":"2020-04-20T11:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=480221"},"modified":"2020-04-20T11:24:01","modified_gmt":"2020-04-20T11:24:01","slug":"postherpetic-neuralgia-market-insights-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/postherpetic-neuralgia-market-insights-epidemiology-and-market-forecast-2030_480221.html","title":{"rendered":"Postherpetic Neuralgia Market Insights, Epidemiology and Market Forecast 2030"},"content":{"rendered":"
\"Postherpetic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Postherpetic Neuralgia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight’s “Postherpetic Neuralgia – Market Insights, Epidemiology, and Market Forecast-2030<\/a>” report delivers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

“The disease is not common under the age of 40 years, but in herpes zoster virus affected persons older than 60 years, it occurs in more than 50%.”<\/strong><\/p>\n

\"\"<\/strong><\/p>\n

Key benefits of the report:
<\/strong>1. Postherpetic Neuralgia market report covers a descriptive overview and comprehensive insight of the Postherpetic Neuralgia Epidemiology and Postherpetic Neuralgia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Postherpetic Neuralgia market report provides insights on the current and emerging therapies.
3. Postherpetic Neuralgia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Postherpetic Neuralgia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Postherpetic Neuralgia market.<\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-market<\/p>\n

Scope of the Report:
<\/strong>1. The report covers the descriptive overview of Postherpetic Neuralgia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
2. Comprehensive insight has been provided into the Postherpetic Neuralgia epidemiology and treatment in the 7MM
3. Additionally, an all-inclusive account of both the current and emerging therapies for Postherpetic Neuralgia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
4. A detailed review of Postherpetic Neuralgia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
5. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Postherpetic Neuralgia market<\/p>\n

Report Highlights:
<\/strong>1. In the coming years, Postherpetic Neuralgia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
2. The companies and academics are working to assess challenges and seek opportunities that could influence Postherpetic Neuralgia R&D. The therapies under development are focused on novel approaches to treat\/improve the disease condition       
3. Major players are involved in developing therapies for Postherpetic Neuralgia. Launch of emerging therapies will significantly impact the Postherpetic Neuralgia market
4. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Postherpetic Neuralgia
5. Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities<\/p>\n

Table of Contents:<\/strong><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Postherpetic Neuralgia<\/span><\/p>\n

3. Competitive Intelligence Analysis for Postherpetic Neuralgia<\/span><\/p>\n

4. Postherpetic Neuralgia: Market Overview at a Glance<\/span><\/p>\n

4.1. Postherpetic Neuralgia Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Postherpetic Neuralgia Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Postherpetic Neuralgia: Disease Background and Overview<\/span><\/p>\n

5.1. Introduction<\/span><\/p>\n

5.2. Sign and Symptoms <\/span><\/p>\n

5.3. Pathophysiology <\/span><\/p>\n

5.4. Risk Factors <\/span><\/p>\n

5.5. Diagnosis <\/span><\/p>\n

6. Patient Journey<\/span><\/p>\n

7. Postherpetic Neuralgia Epidemiology and Patient Population<\/span><\/p>\n

7.1. Epidemiology Key Findings<\/span><\/p>\n

7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

7.3.1. Postherpetic Neuralgia Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n

7.4. United States Epidemiology<\/span><\/p>\n

7.4.1. Postherpetic Neuralgia Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

7.5.1. Germany Epidemiology<\/span><\/p>\n

7.5.1.1. Postherpetic Neuralgia Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n

7.5.2. France Epidemiology<\/span><\/p>\n

7.5.2.1. Postherpetic Neuralgia Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n

7.5.3. Italy Epidemiology<\/span><\/p>\n

7.5.3.1. Postherpetic Neuralgia Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n

7.5.4. Spain Epidemiology<\/span><\/p>\n

7.5.4.1. Postherpetic Neuralgia Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n

7.5.5. United Kingdom Epidemiology<\/span><\/p>\n

7.5.5.1. Postherpetic Neuralgia Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

7.5.6. Japan Epidemiology<\/span><\/p>\n

7.5.6.1. Postherpetic Neuralgia Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

8.1. Postherpetic Neuralgia Treatment and Management<\/span><\/p>\n

8.2. Postherpetic Neuralgia Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Postherpetic Neuralgia Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

11.1. List of Marketed Products in the 7MM<\/span><\/p>\n

11.2. Drug Name: Company Name<\/span><\/p>\n

11.2.1. Product Description<\/span><\/p>\n

11.2.2. Regulatory Milestones<\/span><\/p>\n

11.2.3. Other Developmental Activities<\/span><\/p>\n

11.2.4. Pivotal Clinical Trials<\/span><\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

12. Emerging Therapies<\/span><\/p>\n

12.1. Key Cross<\/span><\/p>\n

12.2. Drug Name: Company Name<\/span><\/p>\n

12.2.1. Product Description<\/span><\/p>\n

12.2.2. Other Developmental Activities<\/span><\/p>\n

12.2.3. Clinical Development<\/span><\/p>\n

12.2.4. Safety and Efficacy<\/span><\/p>\n

12.2.5. Product Profile<\/span><\/p>\n

List to be continued in report<\/span><\/p>\n

13. Postherpetic Neuralgia: Seven Major Market Analysis<\/span><\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Postherpetic Neuralgia Market Size in 7MM<\/span><\/p>\n

13.3. Postherpetic Neuralgia Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

15.1. United States: Market Size<\/span><\/p>\n

15.1.1. Postherpetic Neuralgia Total Market Size in the United States<\/span><\/p>\n

15.1.2. Postherpetic Neuralgia Market Size by Therapies in the United States<\/span><\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n

15.3. Germany Market Size<\/span><\/p>\n

15.3.1. Postherpetic Neuralgia Total Market Size in Germany<\/span><\/p>\n

15.3.2. Postherpetic Neuralgia Market Size by Therapies in Germany<\/span><\/p>\n

15.4. France Market Size<\/span><\/p>\n

15.4.1. Postherpetic Neuralgia Total Market Size in France<\/span><\/p>\n

15.4.2. Postherpetic Neuralgia Market Size by Therapies in France<\/span><\/p>\n

15.5. Italy Market Size<\/span><\/p>\n

15.5.1. Postherpetic Neuralgia Total Market Size in Italy<\/span><\/p>\n

15.5.2. Postherpetic Neuralgia Market Size by Therapies in Italy<\/span><\/p>\n

15.6. Spain Market Size<\/span><\/p>\n

15.6.1. Postherpetic Neuralgia Total Market Size in Spain<\/span><\/p>\n

15.6.2. Postherpetic Neuralgia Market Size by Therapies in Spain<\/span><\/p>\n

15.7. United Kingdom Market Size<\/span><\/p>\n

15.7.1. Postherpetic Neuralgia Total Market Size in the United Kingdom<\/span><\/p>\n

15.7.2. Postherpetic Neuralgia Market Size by Therapies in the United Kingdom<\/span><\/p>\n

15.8. Japan Market Outlook<\/span><\/p>\n

15.8.1. Japan Market Size<\/span><\/p>\n

15.8.2. Postherpetic Neuralgia Total Market Size in Japan<\/span><\/p>\n

15.8.3. Postherpetic Neuralgia Market Size by Therapies in Japan<\/span><\/p>\n

16. Access and Reimbursement Overview of Postherpetic Neuralgia<\/span><\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/span><\/p>\n

About DelveInsight:<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Postherpetic Neuralgia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-480221","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=480221"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480221\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=480221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=480221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=480221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}